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Appeared at the beginning of the 20th century, allergen-specific immunotherapy (SIT) has long
been used in allergic rhinitis and asthma without any knowledge of its mechanisms of action or
any tangible proof of its efficacy. However, from the beginning of the era of evidence-based
medicine, a number of placebo-controlled studies have been published and reached a sufficient
number to assess the cellular events induced by SIT and allow meta-analysis to provide guide-
lines based on proofs. Controlled studies and meta-analysis concerned not only subcutaneous
immunotherapy but also the sublingual route, demonstrating an effect of SIT on symptoms and
medication use. Most recently sublingual tablets were proposed in allergic rhinitis. This paper
reviews the mechanisms of SIT, the evidence of efficacy of SIT from the injective to the sublin-
gual route and reminds the current guidelines.
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Together with allergen avoidance, allergen-specific immu-
notherapy (SIT) is the only available treatment able to
affect the natural course of allergy. It is validated for
IgE-mediated sting allergies and respiratory allergies, i.e.
allergic rhinitis and asthma. Since the first use of SIT in the
early 20th century,1 a large amount of clinical trials have
been conducted and published, most of them being
placebo-controlled. These trials made SIT become an
evidence-based treatment and brought insights into SIT
mechanisms, efficacy and safety. These insights served to
figure out indications and contra-indications of SIT, and the
necessary rules to be applied to improve the benefit/risk
ratio of this treatment. These rules were relayed in inter-
national guidelines. More recently, allergen extracts were
successfully proposed as sublingual tablets in allergic
rhinitis. In this review, we will review the mechanisms of
SIT, go through the main published clinical data concerning
SIT in allergic respiratory diseases, insist on most recent
papers, and remind the current guidelines.
Allergen-specific immunotherapy: a model of
immunomodulation in humans
Prevention of inflammation in response to non-dangerous
antigens has long been a major issue in clinical immunology,
with a variable success in organ transplantation, auto-
immune and allergic diseases through the use of controller
drugs such as corticosteroids, calcineurin inhibitors and
more recently monoclonal antibodies. However, these
drugs are not antigen specific and therefore induce a state
of immunosupression. They also induce some adverse non-
immunological effects. In the field of allergy, however,
antigen-specific immunotherapy drives the immune system
to tolerate allergens without controllers in the long term.
This antigen-specific immunomodulation is a unique and
inestimable tool to understand not only the treatment, but
also the disease it cures.
Allergy is currently considered as a peculiar case of an
inflammatory reaction, in which the antigen is an allergen,
and the host an allergic subject. Because it is an allergenpenetrating into an allergic organism, the antigen presen-
tation results in a Th2 differentiation of specific T cells (Fig.
1). Schematically Th2 cells, by producing IL-4 and IL-13,
trigger the IgE synthesis, while by producing IL-5 they
attract and activate eosinophil polymorphonuclear cells.
Then IgEs bind their high affinity receptor (FceRI) on
effector cells such as mast cells and in case of continuous
exposure or re-exposure induce mast cell degranulation,
histamine and leukotriene release and the early phase of
the allergic reaction. In parallel, in the presence of aller-
gens, IgEs bind to B cells and other antigen presenting cells
through the low affinity receptor of IgE, CD23. Eosinophils,
through their production of basic proteins, injure epithelia,
organize the late phase response and the chronic allergic
reaction. SIT acts at each step of the allergic reaction: IgE
and IgG productions, mast cell and eosinophil homing, T cell
activation, and antigen presentation.
Action of SIT on Ig production
The elevation of specific IgG during SIT, notably IgG4, was
described a long time ago,2,3 and confirmed more recently.4
Although they can be involved in allergic reactions, IgG4 are
widely considered as blocking antibodies, preventing the
allergen to encounter IgE bound on Fc3RI at the surface of
effector cells and antigen presenting cells. The blocking
antibodies also prevent the binding of allergeneIgE
complexeson the lowaffinity receptor for IgEat thesurfaceof
B cells, thus decreasing the capacity of B cells to present the
allergen to specificTcells. Indeed, adramaticdecreaseunder
SIT vs. placebo of the IgE binding to B cells in grass pollen
allergy was shown.5 This action of blocking antibodies was
also shown in birch allergy.6 Most recently, a parallelism
between the inhibition of early skin response, histamine
release, IgG binding to B cells and IgG4 increase was demon-
strated.7 Another hypothesis for the action of IgG4 during SIT
is the preferential engagement of the B isoform of the low
affinity receptor to IgG (FcgRIIB) by IgG4eallergen complexes
onmast cells that would induce a deactivation signal through
phosphorylation of immunoreceptor-based inhibition motifs
(ITIM) activating intracellular phosphatases, counter-
balancing the effect of immunoreceptor-based activation
motifs (ITAMs) present in the intracellular tail of Fc3RIg.8
Figure 1 Antigen presentation results in a Th2 differentiation in allergy, leading to the eosinophil and mast cell mediated
inflammatory reaction. Specific immunotherapy (SIT) acts both on antigen presenting cells and T cells to prevent symptoms.
Ag: antigen, APC: antigen presenting cell.
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A decrease in tissue infiltration by eosinophils was shown
during sublingual immunotherapy to house dust mites.9 In
this study, the conjunctival infiltration by eosinophils was
decreased after challenge by allergens in the treated group
but not in the placebo group. Importantly after 2 years of
treatment, the lower infiltration by eosinophils was found
before challenge in the treated group compared to
placebo. During subcutaneous SIT against grass pollen
allergy, an inhibition of eosinophil migration into the nasal
mucosa after challenge10 was demonstrated by a decrease
in intra-epithelial eosinophil infiltrate.
With regard to mast cells, apart the effects related to
the IgG4/IgE increase, a decrease of the allergen-induced
c-kit positive cell infiltration of the nasal mucosa has been
shown after grass pollen SIT compared to placebo.11Action of SIT on T cell activation
It is in the field of T cell activation that the main studies on
SIT mechanisms have been published in the last decade.
After the discovery of the Th2 model in the early 1990s, it
was postulated that SIT was able to trigger a Th2 to Th1
switching of T cell activation, thus inhibiting eosinophils,
mast cells and IgE production and drive the isotypic
commutation towards IgG4. Indeed, Secrist demonstrated in
blood that allergen stimulation was inducing IL-4 production
in non-treated patients and IFN-g in patients desensitized to
house dust mites or grass pollen.12 Accordingly, an increase
of IFN-g producing T cells was observed upon pollen chal-
lenge in treated rhinitic patients.13
Hymenoptera venom allergy provided a paradigm for the
study of T cell activation during SIT. Indeed hymenopteravenom allergic patients selected for immunotherapy
constitute a homogeneous group of patients, all having
experienced a generalized anaphylactic reaction after
a unique allergen challenge. In addition, as being usually
non-atopic, these patients’ immune system do not respond
to other allergens during treatment, and thus SIT effects on
T cells are easier to detect. Lastly, SIT is considered as
regularly efficient in these patients, which strengthen the
reliability of this experimental model. The Th2 to Th1 shift
was first reported in venom SIT.14 However, in bee venom
allergy, the ex-vivo stimulation of T cells by PLA2, the main
allergen in bee venom, induced an extinction of both Th1
and Th2 cytokine release in treated patients. By contrast,
a dramatic increase of IL-10 production was observed
during SIT.5,15 IL-10 is a potent immunosuppressive cyto-
kine, well known to be involved in tolerance induction and
maintenance. It was, however, only in the early 2000s that
T regulatory cells (Treg) were identified as IL-10 producers
during SIT. Treg cells represent small populations of T cells,
able to produce IL-10 and/or TGF-beta, another immno-
suppressive cytokine. Among Treg cells, the natural subset,
expressing CD4 and CD25 at a high level together with the
transcription factor fox p 3, is the most studied to date.
Several papers were published within the last years about
Treg cells in allergy and other inflammatory diseases,
pointing out a Treg deficiency as responsible for many of
them. It is probably excessive to consider the Treg cell
impairment as the primum movens of allergy in all patients,
as it can also reflect the consequence of inflammation and
as the relevance of fox p 3 detection as a proof of their
regulatory phenotype is debated.16 Nevertheless,
CD4þ CD25þ cells were shown to be decreased and inef-
fective in grass17 and birch pollen and house dust mite
allergies.18 During SIT against grass pollen19 and venom,20
an increase in Treg cell activation was shown. We
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CD4þ CD25þ high T cells and of IL-10 producing T cells
during venom SIT, paralleled with a Th2 to Th1 shift. This
effect of SIT was detectable as soon as 6 h after the first SIT
injection. Importantly, results differed between patients
having experienced severe vs. non-severe reactions, with
an early increase of Treg cells in the latter, associated to
a clearer IL-10- and IFN-g-positive cells ascension in this
group.21 Most recently, we showed that in bee venom SIT,
adverse anaphylactic reactions induced by the treatment
itself were related to an absence of Treg and IL-10þ cell
induction, and of the Th2 to Th1 switch, making this
phenomenon a potential tool to set up SIT progression
(Botturi, in preparation). Indeed in patients with an
absence of early Treg increase upon SIT, intermediate doses
could be administered during the treatment to prevent
adverse events. Interestingly, such strategy can be
proposed because of a very early modification of T cell
activation during SIT (after 4 h), which contrasts with the
modification in Ig concentrations that are not related to the
clinical benefit.
In grass pollen allergy, an increase of IL-10 positive cells
infiltrating the nasal mucosa of challenged patients after
SIT was shown vs. placebo.5 Interestingly the IL-10 increase
paralleled the skin late phase response inhibition.7
Completing the picture, Fox p 3þ CD4þ CD25þ T cells
were detected in the nasal mucosa after SIT,22 as well as
TGF-betaþ cells.23 It is noteworthy that SIT-induced IL-10
production is not limited to T cells. Indeed it was well
demonstrated in B cells and monocytes during bee venom
allergy,15 and in macrophages during seasonal rhinitis.5
A few studies concerned the mechanisms of sublingual
immunotherapy, and the recent publications suggest that
the mechanisms involved are similar as those involved in
the injective route. In birch allergy, Bohle and colleagues
detected an increase of circulating CD4þ CD25þ cells, of
IL-10 and fox p 3 gene expression as early as 4 weeks after
the onset of sublingual SIT.24
Concerning the SIT action on T cell activation, it must be
said that1 the induction of Treg cells was probably detected
as early as 1980 in a paper demonstrating the presence of
a cell population in desensitized patients inhibiting the
proliferation of ragweed specific T cells in desensitized
patients only,25 and 2that almost all the literature concerns
the injective route.Action of SIT on innate immunity
Above T cells, SIT acts on antigen presenting cells them-
selves. This is of matter since this action de facto proves
a non-allergen-specific role of SIT. This non-specific action
could be suspected by considering the number of T cells
involved in the Treg increase and/or the Th2 to Th1 shift.
Indeed this number is too high to reflect allergen-specific
T cells only, and necessarily bystander non-specific T cells
are involved. This possible implication of bystander T cells26
could be relevant to the known effect of SIT on the natural
history of allergy, notably new sensitizations.27
SIT is administered as purified and standardized extracts
that contain allergens accompanied by non-proteic
components able to bind to toll like receptors (TLR) presentat the surfaces of professional antigen presenting cells
(APCs) and non-professional APCs (epithelial cells, B cells,
endothelial cells, etc). These motifs called pathogen-
associated molecular patterns (PAMPS) include small
sequences of nucleic acids such as single or double strand
RNAs, CpGs, or saccharides or lipopolysaccharides. The
binding of TLR by PAMPS induces APC to differentiate into
cells inducing one or another kind of T cell differentiation
independently of the nature of the antigen itself.28 It is
likely that during SIT, PAMPS associated to allergens but
also to other proteins present in the extract orientate APC
in a pro-Th1 or a pro-Treg profile, thus participating to the
immune effect induced by SIT. It is also possible that
because of the route, rhythm and dose of allergen admin-
istered, the APC behaves in a different manner than it does
when the exposure is natural, and therefore orientates
T cells to a tolerant pathway. Beyond these speculations,
several studies have demonstrated an effect of SIT on
innate immunity. During venom SIT, Akoum showed that the
SIT-induced decrease of IL-4 by T cells was seen only after
ex-vivo stimulation by the allergen, whereas the increase in
IFN-g production was visible without ex-vivo stimulation.29
In this model, we reported an increase of IL-12, a pro-Th1
cytokine, by blood monocytes.30 In the nasal mucosa, SIT
induces IL-12 producing cells.31 This effect of SIT on innate
immunity is probably important, and questions the rele-
vance of using recombinant allergens for immunotherapy,
unless they are associated to non-specific adjuvants such as
PAMPS.32 The effect of SIT on cells belonging to the innate
immunity is not limited to IL-12 production. Indeed several
works clearly demonstrated that monocytes and macro-
phages were producing IL-10 in treated patients.5,15
With regard to the sublingual route, a recent study
showed that a TLR-2 agonist able to trigger the IL-10 and IL-
12 productions by dendritic cells inducing in turn T cell-IL-
10 and IFN-g productions was able to enhance the effect of
sublingual ovalbumin in a model of ovalbumin-induced
asthma.33 A similar strategy was already used in humans by
coupling a TLR 9 agonist, i.e. CpG sequences, to Amb A 1,
a recombinant form of the major allergen of ragweed.
A prolonged effect on rhinitic symptoms was obtained with
the use of a weekly injection during pollen season.31Allergen-specific immunotherapy: an
evidence-based treatment of allergy
The efficacy of SIT has long been a matter of debate.34,35
Indeed, it has been considered as an adjunctive treatment
with poor efficacy as long as controlled trials were not
available. Furthermore, as SIT is not effective for all the
allergens used, nor in all the patients treated, it has been
very difficult, despite its ancient availability, to convince
the scientific community of its efficacy. Lastly, it must be
said that it is especially difficult to demonstrate an effect
for allergen-specific immunotherapy. Indeed, in allergic
diseases, placebo effect is always consistent, especially
when the treatment consists of repeated injections. The
fact that increasing doses of a vaccine are injected adds
some irrational beliefs in the efficacy, increasing the
placebo effect. Furthermore, it is especially difficult to
embark patients in a long-term trial against placebo, using
804 A. Pipet et al.the injective route. Such trials are particularly difficult to
set up for children in whom they are felt as unacceptable.
However, since a couple of decades, a large work of anal-
ysis of old trials and of setting of new trials has been done,
giving to SIT its nobility and making it considered as an
evidence-based treatment of allergy.Efficacy of subcutaneous immunotherapy (SCIT) in
allergic rhinitis
Allergic rhinitis is certainly the disease in which SCIT effi-
cacy is the most documented and proved. A meta-analysis
was published in 2007 in the frame of the Cochrane
collaboration.36 Fifty-one trials including a total of 2871
participants were considered. None of them was con-
ducted exclusively in children, but participants younger
than 18 years of age were included in 9 studies. Allergens
tested were ragweed (nZ 12), mixed grass (nZ 16),
timothy (nZ 5), parietaria (nZ 6), birch (nZ 4), orchard
(nZ 2), cedar (nZ 3), bermuda (nZ 1), juniperus ashei
(nZ 1) and cocos (nZ 1). Fifteen studies suitable for
symptom score analysis demonstrated a significant reduc-
tion (standardized mean difference (SMD): 0.73, 95% CI:
0.97 to 0.50, p< 0.00001). The medication score
analysis (13 studies) showed a significant reduction in the
SIT group (SMD: 0.57, 95% CI: 0.82 to 0.33,
p< 0.00001). It is of note that there was a significant
heterogeneity among these studies. Passalacqua and
colleagues37 updated this work in the frame of the GA2LEN
network by collecting 15 recent studies published between
2000 and 2006. Reduction of symptoms and/or need for
medications were confirmed with grass, birch, parietaria
and ragweed pollens, and house dust mites (HDM). In
addition, SCIT treated patients’ quality of life significantly
improved.38e40
It is for allergic rhinitis that the duration of SCIT effect is
the best documented. In 1988 Mosbech and colleagues41
had reviewed after 6 years of discontinuation of SCIT for
grass pollen allergy 38 patients treated initially for 2.5
years. Symptom scores had remained unchanged at review.
A cohort of 22 patients with previous SCIT was reviewed 12
years after discontinuation of therapy.42 Again, symptom
and medication scores were still better in treated patients
compared to controls. Des Roches and colleagues43 fol-
lowed-up for 3 years every 6 months a cohort of 40 patients
desensitized for a period of 12e96 months. Fifty per cent of
patients had relapsed after 1 year and 60% at the end of the
3 years of follow-up. The authors showed that the shorter
was the treatment, the earlier was the relapse. Naclerio
and colleagues conducted a 3-year controlled study in 20
patients.44 After 3 years of ragweed immunotherapy,
patients were randomized to receive either maintenance
injections or placebo. Nasal challenges had been performed
before treatment, and repeated before and 1 year after
randomization. At the end of the 3 years course of SIT,
symptoms had decreased as well as nasal challenge
responses. One year after randomization, nasal challenges
showed partial recrudescence in patients under placebo
and remained inhibited in patients still treated. However,
symptoms did not relapse in any group during the pollen
season. Lastly, Durham and colleagues conducted a 3-yearstudy in which three groups of grass allergic patients were
followed-up as to their symptom and medication scores
among three successive pollen seasons.45 In two groups
(32 patients), SCIT had already been administered since 2
years, the last being a non-desensitized control group
(15 patients). In the first treatment group, SCIT was main-
tained for 3 additional years whereas in the second it was
discontinued and replaced by placebo. In both immuno-
therapy groups, scores did not vary throughout the three
seasons, remaining significantly decreased compared to the
non-desensitized group.
Patients included in the PAT study,46 a 3-year random-
ized, placebo-controlled trial, conducted in 205 grass and/
or birch pollen allergic children, were followed after the
end of the study.47 A persistent clinical effect on
conjunctivitis and rhinitis, evaluated on Visual Analogue
Scale, was demonstrated 7 years after the study.
All these studies therefore clearly indicate a remnant
effect of SIT after discontinuation of the treatment.Efficacy of SCIT in allergic asthma
The proof of SIT efficiency in asthma has long been served
by a meta-analysis by Abramson and colleagues, first pub-
lished in 1995,48 and then kept regularly up to date in the
frame of the Cochrane Institute.49e51 The last update
includes 75 controlled trials (23 studies added since the
previous update), among which a large majority is double
blind, placebo-controlled. These studies concern house
dust mites (nZ 36), pollen (nZ 20), animal dander
(nZ 10), cladosporium (nZ 1), latex (nZ 1), and 6 further
studies were using multiple allergens. This meta-analysis
shows that globally 4 patients have to be treated by SIT to
prevent one asthma attack and that 5 patients must be
treated to prevent an increase of symptoms. Furthermore,
it demonstrates that SIT in asthma results in a reduction of
related medications, with a standardized mean difference
(SMD) of 0.8 (95% CI: 1.13 to 0.48). Although asthma
symptom and medication scores improved, the meta-anal-
ysis still failed to demonstrate a statistically significant
effect of SIT on lung function, probably due to the
heterogeneity of parameters measured, and to the limited
size of the effect. A modest but significant effect of SIT
(SMD: 0.43, 95% CI: 0.71 to 0.14) on non-specific
bronchial hyperreactivity was shown. With regard to
specific bronchial hyperreactivity, the effect was more
consistent (SMD: 0.66, 95% CI: 0.87 to 0.45), and was
the highest for house dust mites. Concerning immuno-
therapy with multiple allergens in polysensitized patients,
the results were negative.
Some recent well-conducted studies do not figure the
meta-analysis but confirm the data. Three studies, two in
adults52,53 and one in children54 were conducted in asth-
matics allergic to house dust mite, and demonstrated a high
efficacy on symptom and medication scores, and also on
bronchial hyperreactivity. In birch pollen allergy, a 2-year
study confirmed the efficacy of this treatment,55 with again
a significant decrease of clinical scores. In children with
grass pollen allergy and seasonal asthma, seasonal SIT
improved symptom scores and specific bronchial, conjunc-
tival and cutaneous reactivity.56
Allergen-specific immunotherapy in allergic rhinitis and asthma 805Thus, the proofs of subcutaneous SIT efficacy in asthma
are built on at least 80 clinical trials. Again it is likely that
some negative studies were not published, but the first
version of Abramson’s meta-analysis estimated already at
33 the number of studies necessary to inverse the conclu-
sions driven.48
Efficacy of sublingual immunotherapy (SLIT)
Because of the constraint due to the injective route, many
efforts were done during the last 15 years to develop some
oral immunotherapy. Most recent SIT studies concerned the
sublingual route and were conducted throughout the last 10
years. To date, SLIT has been tested in rhinitis and asthma
in about 40 double blind, placebo-controlled studies
(sources: MEDLINE database). As most of these studies were
included in the meta-analyses described below, they will
not be described in detail. Indeed, 4 meta-analyses were
published in the frame of the Cochrane collaboration57 or
with the Cochrane collaboration method58e60 (Tables 1 and
2). For all these meta-analyses the methodology consists of
systematically reviewing the main databases including at
least MEDLINE, EMBASE and the Cochrane Library, and then
select double blind, placebo-controlled trials. Some meta-
analyses also include open studies. Wilson and colleagues57
considered 22 trials (979 patients) mixing adults and chil-
dren with allergic rhinitis and/or asthma in a meta-analysis
where pollen (grass: nZ 5, parietaria: nZ 5, olive tree:
nZ 2, ragweed: nZ 1, tree: nZ 1, cypress: nZ 1) more
than indoor allergen extracts (house dust mites: nZ 6, cat:
nZ 1) were used. Despite the heterogeneity within studies
in the age of the enrolled patients, the allergens employed,
the scoring systems used and the durations of treatment
chosen, conclusions could be driven: a significant reduction
of symptom score and the primary outcome in all the
studies included (SMD: 0.42, 95% CI: 0.69 to 0.15,
pZ 0.002) was demonstrated, along with a marked reduc-
tion of medication scores (SMD: 0.43, 95% CI: 0.63 to
0.23, pZ 0.00003). Importantly, subgroup analysis failed
to show a significant effect of house dust mite extracts
(studiesZ 6, subjectsZ 118, SMD: 0.58, 95% CI: 1.43 to
0.27, pZ 0.18). SLIT to cat could not be analysed because
of a single trial meeting the required criteria to enter the
meta-analysis. When considering separately adults andTable 1 Published meta-analyses regarding SLIT and SCIT.
Abramson
et al. (2003)51
Calderon
et al. (2007)75
Wilson
et al. (20
Route SCIT SCIT SLIT
Disease Asthma Rhinitis Rhinitis
N studies 75 51 22
N patients 3506 2871 979
Age Adultsþ children Adultsþ children Adultsþ
Symptom
score SMD
(95% CI)
0.72
(0.99 0.33)
0.73
(0.97 to 0.50)
p< 0.00001
0.42
(0.69 
pZ 0.00
Medication
Score
SMD (95% CI)
0.8
(1.13 to 0.48)
0.57
(0.82 0.33)
p< 0.00001
0.43
(0.63 
pZ 0.00
SMDZ standardized mean difference.children, the results were positive for adults (nZ 16, sub-
jectsZ 741, SMD: 0.4, 95% CI: 0.61 to 0.18,
pZ 0.0003), but clearly negative for children (nZ 5, sub-
jectsZ 218, SMD: 0.31, 95% CI: 1.32 to 0.7, pZ 0.5).
However, the small number of studies and subjects in each
subgroup and their heterogeneity incite to consider nega-
tive results cautiously. No conclusion was driven about
asthma alone.
Another meta-analysis focused on rhinitis in children.58
Among 70 articles reviewed, only 10 fulfilled the selection
criteria (total 577 patients, 484 evaluable), and were
included. Again, the significant heterogeneity among
studies should be noticed. Here, a significant reduction of
both symptoms and medication use was found (respec-
tively, SMD: 0.56, 95% CI: 1.01 to 0.10, pZ 0.02, and
SMD: 0.76, 95% CI: 1.46 to 0.06, pZ 0.03). The higher
number of children included (484 against 218), and the
paediatric specificity of this study probably accounts for
this difference with the Wilson’s study. However, the low
magnitude of the effect observed must be considered.
The sub-analysis according to the allergens used
confirmed the significant effect to be due to pollen and not
house dust mite extracts.
A recent additional meta-analysis in children with
allergic asthma including 9 studies in 441 children allergic
to house dust mites (6 studies) or pollen (3 studies),59
concluded to an effect of SLIT on both symptom score (SMD:
1.14, 95% CI: 2.1 to 0.18) and medication score (SMD:
1.63, 95% CI: 2.83 to 0.44) (Table 1). No subgroup
analysis according to the allergens used was done, but the
authors indicated that reduction in asthma symptoms was
constant in 5 of the evaluated studies, ‘‘particularly in
those where mite extracts were used’’.
A last meta-analysis focused on asthma.60 Twenty-five
studies were retained, with 6 open clinical trials. A signif-
icant improvement in asthmatic symptoms considered as
categorical outcomes was observed in 7 studies (876
patients, RRZ 0.48). Interestingly, 4 studies (144 patients)
showed a significant improvement in FEV1, and FEV2 studies
an improvement in FEF25e75. However, the effect on
asthma symptoms considered as continuous outcomes and
medication score were not significant (SMD: 0.38, 95% CI:
0.79 to 0.03; SMD: 0.91, 95% CI: 1.94 to 0.12,
respectively).05)57
Penagos
et al. (2006)58
Calamita
et al. (2006)60
Penagos
et al. (2008)59
SLIT SLIT SLIT
Rhinitis Asthma Asthma
10 25 9
577 1706 441
children Children Adultsþ children Children
0.15)
2
0.56
(1.01 0.1)
pZ 0.02
0.38
(0.79 0.03)
NS
1.14
(2.1 0.18)
pZ 0.02
0.23)
003
0.6
(1.46 0.06)
pZ 0.03
0.91
(1.94 0.12) NS
1.63
(2.83 0.44)
pZ 0.007
Table 2 Heterogeneity between studies about SLIT.
Wilson et al. (2005)57 Penagos et al. (2006)58 Calamita et al. (2006)60 Penagos et al. (2008)59
Population Adultsþ children Adultsþ children Children 3e18 years Children 3e18 years
Years of publication 1966e2002 1966e2005 1966e2006 1966e2006
Allergens House dust mites(nZ6) Pollen(nZ14) Grass pollen(nZ4) House dust mites(nZ6)
Grass pollen(nZ5) House dust mites(nZ8) House dust mites(nZ4) Grass mix(nZ1)
Parietaria(nZ5) Mix of allergens(nZ2) Parietaria(nZ1) Olea europaea(nZ1)
Olive(nZ2) Latex(nZ1) Olive(nZ1) Pollen mix(nZ1)
Ragweed(nZ1)
Cat(nZ1)
Tree(nZ1)
Cupressus(nZ1)
Symptoms considered Rhinitis AsthmaRhinitis Rhinitis Asthma
Duration of studies 2e24 months 3 monthse3 years 3e36 months 3e32 months
806 A. Pipet et al.These meta-analyses therefore show SLIT to be efficient
in pollen-induced rhinitis and asthma, both in adults and
children, but indicate that more investigations must be
provided to prove the efficacy of SLIT in house dust mite
allergy. In addition it is noteworthy that1 in some pollen
studies, positive results were delayed to the second year of
treatment61,62 and 2studies using a mix of various pollen
extract are negative,63 or marginally positive.64
Some additional recent studies were not included yet in
meta-analyses. One recent double blind, placebo-
controlled study is available with cat standardized
extracts.65 The main outcomes were symptom scores and
peak expiratory flow (PEF) during exposure to a cat in a cat-
room, after 1 year of treatment. All patients suffered from
rhinoconjunctivitis, and 75% from asthma. Symptoms and
PEF significantly improved in the treatment group. It is
noteworthy that cat exposure in a cat-room cannot be
considered as reflecting a usual daily exposure, but this
study is the first controlled one showing a significant clinical
effect of a sublingual extract for cat allergy. The precedent
study by Nelson et al.66 was negative, but methodological
problems have been pointed up.
The studies reported above were mainly conducted with
sublingual drops of extracts. Recently, sublingual orodis-
persible allergen tablets were developed in grass pollen
immunotherapy, and are expected to rapidly replace the
liquid formulation. An orodispersible grass allergen tablet
75,000 standardized quality tablet (75,000 SQ-T), contain-
ing Phleum pratense allergens (approximately 15 mg of
major allergen Phl p5) was tested in 11 studies. These
allergens were selected for their wide expression in
grasses.67 An international work by Laffer and colleagues,68
including 183 patients allergic to grass pollen from different
populations (Europe, Canada, Japan), showed that
recombinant allergens such as Phl p5 and Phl p1, bound high
levels of timothy grass pollen-specific IgE in all subgroups.
The main originality of the tablet approach is the
administration of a single pollen at a single dose, without
any dose progression. Despite the immediate administra-
tion of a maximal dose of allergen, safety studies were
convincing in adults,69e71 both in rhinoconjunctivitis and
asthma, and more recently in 5e12 years old children72
with a limited number of benign allergic adverse events. A
total of 634 adults from 51 centers in 8 countries wereincluded in a double blind placebo-controlled study to
judge the clinical value of 75,000 SQ-T.73 There was
a significant improvement in rhinoconjunctivitis symptom
and medication scores (reduction of 30% and 38%, respec-
tively, p< 0.0001 for both). In another study, the quality of
life appreciated with the validated RQLQ questionnaire was
improved by 75,000 SQ-T.74 Interestingly, this effect was
higher than this of loratadine. Calderon and colleagues
analysed the results of 3 positive controlled studies and
suggested that a longer preseasonal treatment (8 weeks vs.
4 weeks) improved the clinical efficiency.75 Although 75,000
SQ-T is a single pollen extract administered at a constant
dose, tablets of immunotherapy are also developed as
a mixture of equal proportions of 5 grass pollens (orchard,
meadow, perennial eye, sweet vernal, and timothy grass)
administered at a dose of 300 IR (approximately 25 mg/ml of
the group 5 major allergens) reached after 5 days of titra-
tion.76 In an international randomized, placebo-controlled
double blind study, this tablet immunotherapy reduced the
total rhinoconjunctivitis symptom score by 35%
(pZ 0.0006) in the 500-IR group and 37% in the 300-IR group
(pZ 0.0001). Individual symptom scores, rescue medica-
tion usage, and quality of life were also significantly
improved by treatment. A low dose of 100-IR was ineffi-
cient.76 Although these studies with sublingual tablets of
grass pollen are promising, two studies in house dust mite
allergy provided conflicting results. In the study by Passa-
lacqua and colleagues,77 among rhinitic adults, the
composite asthma and rhinitis clinical score was improved
the first but not the second year of treatment, whereas the
rhinitic symptoms were still improved during the second
year. The medication score was improved only at the first
year.77 The study by Pham-Thi and colleagues was clearly
clinically negative in asthmatic children,78 although skin
sensitivity to house dust mite extracts significantly reduced
and specific IgE and IgG4 significantly increased.
Only a few studies compared the sublingual to the
injective route of SIT79e82 (Table 3). None of them detected
a significant difference between both. However, two were
not placebo-controlled,79,81 which renders difficult the
interpretation of the results. Kinchi and colleagues per-
formed a 2-year study in birch pollen allergic rhinitis. Forty-
eight patients were randomized in three groups: sublingual
tablets, subcutaneous depot extracts and placebo.80 Again
Table 3 Main studies comparing SCIT to SLIT.
Quirino et al. (1996)79 Mungan et al. (1999)82 Khinchi et al. (2004)80 Mauroa et al. (2007)81
Method Double blind
(double-dummy),
but not
placebo-controlled
Randomized,
placebo-controlled
Randomized, double
blind, double-dummy,
placebo-controlled
Randomized but not
placebo-controlled
Disease Rhinitis Rhinitis and asthma RA R
Allergen Grass House dust mites Birch Betulaceae
Ratio SL/SC dose 2.4 w100 w175 w100
N patients 20 36 71/48 47/40
Age Adults Adults Adults Adults
Duration Two pollen seasons 1 year 2 years One pollen season
Medication score SLIT/SCIT: NS SLIT/placebo: p< 0.01 NS between SC and SL NS between SC and SL
SCIT/placebo: p< 0.01 SL/placebo: p< 0.02
SC/placebo: p< 0.002
(first season)
Main symptom
score
SLIT/SCIT: NS SLIT/placebo
p< 0.01 for rhinitis
but NS for asthma
SL/placebo: p< 0.002
SCIT/placebo: p< 0.01 SC/placebo: p< 0.002
(first season)
SLIT/SCIT: NS NS between SC and SL
Immunologic
evaluation
Only in the SC group:
change in IgG4
(p< 0.001)
Increase of IgG4 in both
SLIT and SCIT
No data Only in the SC group:
significant increase in
IgG4 (pZ 0.01)
Safety: systemic
reactions
No data None 29% in the SC group 16% in the SC group
0% in the SL group 0% in the SL group
NSZ not significant.
Allergen-specific immunotherapy in allergic rhinitis and asthma 807this study failed to show a difference between both routes
of SIT. Both treatments improved significantly the symptom
score compared to placebo during the first year. However,
only subcutaneous SIT was efficient on medication score.
During the second season, pollen counts were reduced so
that no conclusion could be driven.
With regard to adherence to treatment, the advantage
of an administration route to another is not established yet.
Some studies found a very high rate of adherence to SLIT,
between 75 and 100%.37,83 In contrast, Pajno and colleagues
in a 3-year study,84 found adherence to the subcutaneous-
route to be higher than this to SLIT, with 10.9% of non-
adherent patients in the former and 21.5% in the latter.
Non-compliance was defined by stopping SIT without the
authorization of the prescribing physician.Does immunotherapy modify the natural
course of allergy?
In addition to its effect on symptom and medication scores,
some studies have showed that immunotherapy was able to
prevent from further sensitizations and to reduce the risk
of asthma in rhinitic subjects. Indeed in a paediatric study
in asthma, Des Roches, during a 3-year follow-up, found
new sensitizations in 11/22 children receiving SIT vs. 22/22
children treated with placebo.27 More recently, Pajno
reported the results of a 6-year follow-up of 123 asthmatic
children allergic to house dust mites85: 75.4% of SIT children
showed no new sensitization after the study, compared to33.3% in the placebo group. Inal and colleagues found quite
similar results among 147 children monosensitized to house
dust mites: 75.3% without any new sensitization after 5
years in the SIT group, vs. 46.7% in the placebo group
(pZ 0.02).86 A retrospective study of 8396 patients
confirmed this protective effect of SIT on the development
of further sensitizations.87 Lastly, an open randomized
controlled study by Marogna and colleagues showed the
same protective effect: the study concerned 216 children
with allergic rhinitis (with or without intermittent asthma),
receiving drugs alone or drugs plus SLIT during 3 years. New
sensitizations appeared in 34.8% of controls and in 3.1% of
SLIT patients (OR 16.85, 95% CI: 5.7349.13). The protec-
tive effect extended to bronchial hyperreactivity, which
significantly decreased in the SLIT group.88
These papers show that SIT not only induces the immune
response towards the allergen used but also commits non-
specifically the immune system to a system tolerating
allergens. This effect could be due first to homology of
structure between allergens. In that case SIT-induced
immunomodulation could be specifically targeting common
epitopes. Another hypothesis which is not demonstrated
yet is the implication of non-specific bystander T cells that
could also explain for example the efficacy of P. pratense
extracts on other grass pollen allergies.26,76
Some data suggest that early SIT could prevent from the
occurrence of asthma. In the frame of the PAT Study, Mo¨ller
and colleagues treated 205 children for seasonal rhinitis to
birch and/or grass pollen.46 Before starting the treatment,
20% of children displayed mild seasonal asthma. After 3
808 A. Pipet et al.years of treatment, the actively treated children had
significantly fewer asthma symptoms than untreated
controls, with an odd ratio of 2.52 (95% CI: 1.3e5.1). A 10-
year follow-up was recently reported: symptoms of asthma
were still less frequent in SIT-treated patients compared to
controls (OR: 2.5, 95% CI: 1.1e5.9), whereas no difference
was found in bronchial responsiveness likely because of an
improvement in the untreated subjects.47 Unfortunately
the study was not placebo-controlled, and these results
must therefore be considered cautiously. Another study
showed that SIT decreases the risk of non-specific bronchial
hyperreactivity in rhinitic patients.89 Novembre and
colleagues enrolled 113 rhinitic children in a 3-year study of
coseasonal sublingual grass pollen SIT, and found a 3.8
times more frequent development of asthma in the control
group after 3 years (95% CI: 1.5e10).90 Further studies must
be prospectively performed to confirm that SIT protects
rhinitic patients from asthma. Notably, it is noteworthy
that these studies concerned pollen-induced seasonal
asthma, which is not the most common form of asthma, and
studies of the effect on SIT on the incidence of persistent
non-seasonal asthma are needed. If true, however, this
preventing effect of SIT on asthma would be a strong
additive reason to treat patients with rhinitis. It would be
interesting to separate analysis of results obtained in adults
from these obtained in children since long-term immuno-
modulation might be age-dependent.Safety aspects
The major risk of subcutaneous immunotherapy is severe
anaphylaxis, with the paradox of giving a high-risk treat-
ment in non-life threatening diseases. This risk must be
considered for subcutaneous SIT at any time, even after
several years of treatment. SIT induces local reactions
which are expected and in the absence of which allergy and
relevance of the treatment must be questioned. In case of
loco-regional reactions, the doses must be reduced and the
re-ascension of doses is more progressive. Syndromic
reactions are frequent (rhinitis, conjunctivitis, asthma) and
must also induce a dose reduction and more progressive re-
ascension.91 Asthma attacks can be severe and mainly occur
in asthmatics. It was clearly shown that the more severe
the asthma the more frequent and severe the SIT-induced
asthma attacks.92 Indeed in the Abramson’s meta-analysis,
among 426 treatments, 28 asthma or rhinitis episodes were
reported, whereas only 7 anaphylaxis and urticaria
occurred.49 Kordash and Miller in the study of 13 fatal cases
between 1992 and 1996 concluded that unstable asthma
was a major risk factor.93 Furthermore, asthma attack can
be delayed to 30 min after the injection whereas other
anaphylactic reactions generally occur in the minutes after
treatment administration.94 A poorly controlled asthma
with frequent symptoms and important individual varia-
tions of FEV1 and peak-flow are considered as risk factors
for SCIT-triggered asthma symptoms. This is why SIT should
not be administered in asthmatic patients with a FEV1
below 70% of predicted values, and why patients must be
kept under surveillance for at least 30 min in a place where
a severe asthma attack can be treated. General reactions,
from generalized urticaria to anaphylactic shock are rare.In a report from the Mayo Clinic,94 an incidence of 0.137% of
general reactions was reported among a total of 79,593
injections. No death was deplored in this series. Between
1985 and 1993, the FDA collected 0.6692 death per million
of injection.95 From a questionnaire sent to AAACI
members, Reid and colleagues reported the occurrence of
17 deaths in 5 years.96 Between 1959 and 1984, 46 deaths
due to SIT were reported in USA.97 Most deaths were due to
dosage mistakes, spacing of injections, inadequate equip-
ment, or unstable asthma. When it is performed with
established security principles, SIT is well tolerated. Indeed
Tabar and colleagues in house dust mite asthmatics repor-
ted local reactions in 10.5% of 419 cases and systemic
reactions in 4.8% of patients (0.37% of injections) with
a rapid response to treatment.98 Luigi and colleagues99 in
another survey reported among 300,086 injections per-
formed from 1968 to 1993 in 6319 asthmatic or rhinitic
patients 184 (0.061%) systemic reactions in 131 (2.1%)
patients. They comprised urticaria (59.3%), mild asthma
(23.9%), asthma associated to urticaria (9.7%) and rhinitis
(7.1%). A more recent retrospective study of accelerated
SIT for various indications including venom allergy reported
systemic reactions in 4.4% of injections.100 Most of these
reactions were mild, and were more frequent in asthmatics
and during protocols using aqueous extracts. Moreno and
colleagues101 reported 53 systemic reactions in 3.7% of 433
patients, showing a great stability over time of the inci-
dence of these adverse reactions.
Sublingual immunotherapy is much safer. Post-marketing
studies reported rare and mild adverse events in adults and
children.102,103 In the update review by Passalacqua,37 only
17 serious adverse reactions during SLIT were reported
among all the controlled studies published between 2000 and
2006. No fatal event has been reported in any study. The rate
of all adverse reactions was 17e60% in the SLIT-treated
groups vs. 8e14% in the placebo-treated groups. They rarely
induced an interruption of the treatment. The majority of
these reactionswas local, verymild (oral itching or swelling),
and self-resolving. Interestingly, adverse effects were
similar in children aged of 5 years or less. With sublingual
grass allergen tablets, no severe side effect was reported in
any study, and most adverse effects were observed at high
non-recommended dosages (>500 IR).104 However, it must
be stressed that the risk of severe anaphylaxis, although
exceptional, still exists with sublingual immunotherapy.105Guidelines
From the large number of studies published, in which the
more important are detailed above, EAACI, AAAAI and WHO
proposed guidelines concerning the use of immunotherapy,
which were published in 1998,106 revised in 2001,107
2007,108 and 2008109 in frame of the ‘‘Allergic Rhinitis and
its Impact on Asthma’’ (ARIA) initiative. These guidelines
are clearly stating the evidence-based use of SIT in the
treatment of rhinitis and asthma. Sublingual immuno-
therapy is recommended for the treatment of pollen
allergy in adults. Considering the lower proof of efficacy for
house dust mites sublingual immunotherapy, SLIT is not
recommended but ‘‘may be used’’ for patients with mite
allergy.
Allergen-specific immunotherapy in allergic rhinitis and asthma 809For the European Academy of Allergy and Clinical
Immunology,110 subcutaneous SIT is indicated in children
above 5 years of age and adults during pollen-induced
allergic diseases (grass, birch, ragweed, olive, parietaria,
cypress), house dust mites and cat allergies when avoid-
ance is not effective. As pollen avoidance is elusive and as
the proof of efficacy of mite avoidance is limited, SIT can
probably largely be considered. Multiple allergen therapy is
not recommended. SLIT is indicated in patients above 5
years of age with allergic rhinoconjunctivitis and asthma,
sensitive to birch, grasses, cypress, olive, parietaria or
house dust mites. SLIT may be considered in patients
insufficiently controlled by antiallergic drugs, such as anti-
histamines and/or inhaled (nasal or bronchial) steroids. The
insufficient control of rhinitis and/or asthma relates to the
persistence of symptoms and use of reliever medications
despite the use of these controllers. However, as asthma
has to be controlled to avoid adverse events of SIT as far as
the injective route is considered, SIT is designed in that
case to decrease the weight of controller treatments rather
than as an add-on therapy. The 2007 ARIA update under-
lines the proved efficiency of specific immunotherapy,
either sublingual or subcutaneous, to reduce bronchial
hyperreactivity and its possibly protecting effect on
asthma. The GINA guidelines111 consider that SIT in asthma
has a limited role. It must be limited to a single well-
defined allergen, after strict environmental avoidance,
with benefits weighed against risks. In the 90s British
guidelines considered that SIT should not be administered
in asthma.112 In the recent actualization of ARIA guide-
lines109 it is stated that SCIT can be considered in patients
with asthma when a clinically significant allergen avoidance
cannot be achieved. Experts warn about the potential risk
of severe allergic reactions during SCIT and advise to fully
discuss this risk with the patients. They do not recommend
SLIT in asthma in routine practice, considering the proofs
insufficient. Concerning primary prophylaxis, they require
more studies to establish the interest of immunotherapy.
Conclusion
A large improvement of immunotherapy techniques and
knowledge of indications have been made from the first use
of this treatment in the early 1900s, so that SIT can confi-
dently be considered as an evidence-based option for
patients with allergic rhinitis and asthma. However,
controlled studies have clearly defined the field of appli-
cation of SIT, and have considerably restrained its appli-
cation. Therefore, this treatment requires some very
rigorous selection of extracts, of patients, and must be
used by trained teams strictly aware of the risks taken.
Recent non-invasive routes of administration are attractive
notably for children, but a large effort of validation is still
to be done.
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